Skip to main content
SpringerLink
Log in

Role of Nitric Oxide in Vascular Dysfunction Associated with Ocular Diseases

  • Chapter
Advances in Ocular Toxicology

  • 92 Accesses

Abstract

Nitric oxide (NO) has emerged as a small, membrane-permeable free radical modulating numerous physiological functions in the cardiovascular, immune, and nervous systems1-5Within the cardiovascular system NO, originally described as endothelium derived relaxing factor, is released by a variety of agonists and cytokines as well as by pulsatile flow and shear stress, and is an important physiological modulator of systemic vascular tone and intravascular fluid volume6’7. Vascular NO functions constitutively to prevent adhesion of platelets and leukocytes and platelet aggregation thereby modulating coagulation and fibrinolyis. In addition, NO affects vascular function by modulating endothelial cell barrier function and vascular smooth muscle proliferation. Derangements in NO production have been linked to a variety of vascular pathologies including septic shock, hypertension, atherosclerosis, acute inflammation, and diabetes mellitus, and the overproduction of NO has been implicated in the pathogenesis of a number of autoimmune diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Moncada S, Higgs E, Hodson H, Knowles R, Lopez-Jaramillo P, McCall T, Palmer M, Redomski M, Rees D, Schulz R. The L-arginine: nitric oxide pathway. J Cardiovasc Pharmacol 1991:17:S1–S9.

    Article  CAS  Google Scholar 

  2. Moncada S, Higgs EA. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 1995;9:1319–1330.

    PubMed  CAS  Google Scholar 

  3. Sessa WC. The nitric oxide synthase family of proteins. J Vase Res 1994;31:131–143.

    Article  CAS  Google Scholar 

  4. Farrell AJ, Blake DR. Nitric oxide. Annals Rheumatic Diseases 1996;55:7–20.

    Article  CAS  Google Scholar 

  5. Schroeder RA, Kuo PC. Nitric oxide: physiology and pharmacology. Anesth Analg 1995;81:1052–1059.

    PubMed  CAS  Google Scholar 

  6. Schini-Kerth VB, Vanhoutte PM. Nitric oxide synthases in vascular cells. Exp Physiol 1995;80:885–905.

    PubMed  CAS  Google Scholar 

  7. Marsden PA, Brenner MB. Nitric oxide and endothelins: novel autocrine/paracrine regulators of the circulation. Semin Nephrol 1991;11:169–185.

    PubMed  CAS  Google Scholar 

  8. Rosenbaum JT, MacDevitt HO, Guss RB, Egbert PR. Endotoxin-induced uveitis in rats as a model for human disease. Nature (Lond) 1980;286:611–613.

    Article  CAS  Google Scholar 

  9. Meijer F, Ruijter JM, Van Delft JL, Van Haeringen NJ. Nitric oxide induces vascular permeability changes in the guinea pig conjunctiva. Eur J Pharmacol 1995;284:61–67.

    Article  PubMed  CAS  Google Scholar 

  10. Meijer F, Van Delft JL, Garrelds IM, Van Haeringen NJ, Kijlstra A. Nitric oxide plays a role as a mediator of conjunctival edema in experimental allergic conjunctivitis. Exp Eye Res 1996;62:359–365.

    Article  PubMed  CAS  Google Scholar 

  11. Stevens MJ, Dananberg J, Feldman EL, Lattimer SA, Kamijo M, Thomas TP, Shindo H, Sima AAF, Greene DA. The linked roles of nitric oxide, aldose reductase and (Na+,K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 1994;94:853–859.

    Article  PubMed  Google Scholar 

  12. Calver A, Collier J, Valiance P. Inhibition and stimulatioin of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992;90:2548–2554.

    Article  PubMed  CAS  Google Scholar 

  13. Smits P, Kapma J-A, Jacobs M-C, Lutterman J, Thien T. Endothelium-dependent vascular relaxation in patients with type I diabetes. Diabetes 1993;42:148–153.

    Article  PubMed  CAS  Google Scholar 

  14. Stuehr DJ, Kwon NS, Nathan C, Griffith O, Feldman P, Wiseman J. Nw-Hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from L-arginine. J Biol Chem 1991;266:6259–6263.

    PubMed  CAS  Google Scholar 

  15. Forstermann U, Kleinert H. Nitric oxide synthase: expression and expressional control of the three isoforms. Naunyn-Schmiedeberg’s Arch Pharmacol 1995;352:351–364.

    Article  CAS  Google Scholar 

  16. Dun NJ, Dun SL, Wu SY, Forstermann U. Nitric oxide synthase immunoreactivity in rat superior cervical ganglia and adrenal glands. Neurosci Lett 1993;158:51–54.

    Article  PubMed  CAS  Google Scholar 

  17. Schmidt HHHW, Gagne GD, Nakane M, Pollock JS, Miller MF, Murad F. Mapping of neural nitric oxide synthase in the rat suggests frequent co-localization with NADPH diaphorase but not with soluble guanylyl cyclase, and novel paraneural functions for nitrinergic signal transduction. J Histochem Cytochem 1992;40:1439–1456.

    Article  PubMed  CAS  Google Scholar 

  18. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 1994;91:5212–5216.

    Article  PubMed  CAS  Google Scholar 

  19. Herdegen T, Brecht S, Mayer B, Leah J, Kummer W, Bravo R, Zimmermann M. Long-lasting expression of JUN and KROX transcription factors and nitric oxide synthase in intrinsic neurons of the rat brain following axotomy. J Neurosci 1993;13(4130–4145)

    PubMed  CAS  Google Scholar 

  20. Zhang ZG, Chopp M, Zaloga C, Pollock JS, Forsternann U. Cerebral endothelial nitric oxide synthase expression after focal cerebral ischemia in rats. Stroke 1993;24:2016–2021.

    Article  PubMed  CAS  Google Scholar 

  21. Kadowaki K, Kishimoto J, Leng G, Emson PC. Up-regulation of nitric oxide synthase (NOS) gene expression together with NOS activity in the rat hypothalamo-hypophysial system after chronic salt loading - arginine vasopressin and oxytocin secretion. Endocrinology 1994;134:1011–1017.

    Article  PubMed  CAS  Google Scholar 

  22. Pollock JS, Nakane M, Buttery LK, Martinez A, Springall D, Polak JM, Forstermann U, Murad F. Characterization and localization of endothelial nitric oxide synthase using specific monoclonal antibodies. Am J Physiol 1993:265:C1379–C1387.

    PubMed  CAS  Google Scholar 

  23. Tracey WR, Pollock JS, Murad F, Nakane M, Forstermann U. Identification of type Ill (endothelial-like) particulate nitric oxide synthase in LLC-PKI kidney tubular epithelial cells. Am J Physiol 1994;266:C22–C26.

    PubMed  CAS  Google Scholar 

  24. Dinerman JL, Dawson TM, Schell MJ, Snowman A, Snyder SH. Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity. Proc Nail Acad Sci 1994;91:4214–4218.

    Article  CAS  Google Scholar 

  25. Nishida K, Harrison DG, Navas JP, Fisher AA, Dockery SP, Uematsu M, Nerem RM, Alexander RW, Murphy Ti. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J Clin Invest 1992;90:2092–2096.

    Article  PubMed  CAS  Google Scholar 

  26. Stuehr DJ, Cho HJ. Kwon NS, Weise MF, Nathan CF. Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein. Proc Nat] Acad Sci 1991;88:7773–7777.

    Article  CAS  Google Scholar 

  27. Bandaletova T, Brouet I, Bartsch H, T. S, Esumi H, Ohshima H. Immunohistochemical localization of an inducible form of nitric oxide synthase in various organs of rats treated with propionibacterium-acnes and 1ipopolysaccharide. APMIS 1993;101:330–336.

    Article  PubMed  CAS  Google Scholar 

  28. Cho Hi, Xie QW, Calaycay J, Mumford RA, Swiderek KM, Lee TD, Nathan C. Calmodulin is a subunit of nitric oxide synthase from macrophages. J Exp Med 1992;176:599–604.

    Article  PubMed  CAS  Google Scholar 

  29. Dimmeler S, Lottspeich F, Brune B. Nitric oxide causes ADP-ribosylation and inhibition of glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem 1992;267:16771–16774.

    PubMed  CAS  Google Scholar 

  30. Clancy RM, Levartovsky D, Leszczynska-Piziak J, Yegudin J, Abramson SB. Nitric oxide reacts with intracellular glutathione and activates the hexose monophosphate shunt in human neutrophils: evidence for Snitrosoglutathione as a bioactive intermediary. Proc Natl Acad Sci USA 1994;91:3680–3684.

    Article  PubMed  CAS  Google Scholar 

  31. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992;258:1898–1902.

    Article  PubMed  CAS  Google Scholar 

  32. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman R. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993;90:7240–7244.

    Article  PubMed  CAS  Google Scholar 

  33. Southan GJ, Szabó C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol 1996;51:383–394.

    Article  PubMed  CAS  Google Scholar 

  34. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y. Wang JL, Sweetland MA, Lancaster JR, Williamson JR, McDaniel ML. Aminoguanidine inhibits nitric oxide formation and prevents diabetic vascular dysfunction. Diabetes 1992;41:552–556.

    Article  PubMed  CAS  Google Scholar 

  35. Cross AH, Misko TP, Lin RF, Hickey WF, Trotter JL, Tilton RG. Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest 1994;93:2684–2690.

    Article  PubMed  CAS  Google Scholar 

  36. Worrall NK, Chang K, Suau GM, Allison WS, Misko TP, Sullivan PM, Tilton RG, Williamson JR, Ferguson TBJ. Inhibition of inducible nitric oxide synthase prevents myocardial and systemic vascular barrier dysfunction during early cardiac allograft rejection. Cire Res 1996;78:769–779.

    Article  CAS  Google Scholar 

  37. Tilton RG, Chang K, Corbett JA, Misko TP, Currie MG, Bora NS, Kaplan HJ, Williamson JR. Endotoxin-induced uveitis in the rat is attenuated by inhibition of nitric oxide production. Invest Ophthalmol Vis Sci 1994;35:3278--3288.

    PubMed  CAS  Google Scholar 

  38. ladecola C, Zhang F, Xu X. Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage. Am J Physiol (Regulatory Integrative Comp Physiol) 1995;268:R286–R292.

    Google Scholar 

  39. Miller MJS, Thompson JH, Zhang X-J, Sadowska-Krowicka H, Kakkis JL, Munshi UK, Sandoval M, Rossi JL, Eloby-Childress S, Beckman JS, Ye YZ, Rodi CP, Manning PT, Currie MG, Clark DA. Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. Gastroenterology 1995;109:1475–1483.

    Article  PubMed  CAS  Google Scholar 

  40. Wu C-C, Ruetten H, Thiemermann C. Comparison of the effects of aminoguanidine and Nw-nitro-L-arginine methyl ester on the multiple organ dysfunction caused by endotoxaemia in the rat. Eur J Pharmacol 1996;300:99–104.

    Article  PubMed  CAS  Google Scholar 

  41. Garvey EP, Oplinger JA, Tanoury GJ, Sherman PA, Fowler M, Marshall S, Harmon MF, Patih JE. Furfine ES. Potent and selective inhibiton of human nitric oxide synthases. J Biol Chem 1994;269:26669–26676.

    PubMed  CAS  Google Scholar 

  42. Hansen OW, Peterson KB, Trivedi M, Moore WM, Currie MG, Manning PT, Connor JR, Pitzele BS. Homopiperidine amidines as selective inhibitors of inducible nitric oxide synthase. Endothelium 1995;3:580.

    Google Scholar 

  43. Marietta MA. Approaches toward selective inhibition of nitric oxide synthase. J Med Chem 1994;37:1899–1907.

    Article  Google Scholar 

  44. Pfeilschifter J, Ederhardt W, Hummel R, Kunz D, Muhl H, Nitsch D, Pluss C, Walker G. Therapeutic strategies for the inhibition of inducible nitric oxide synthase - potential for a novel class of anti-inflammatory agents. Cell Bio Internat 1996;20:5l-58.

    Google Scholar 

  45. Parks DJ, Cheung MK, Chan C-C, Roberge FG. The role of nitric oxide in uveitis. Arch Ophthalmol 1994;112:544–546.

    Article  PubMed  CAS  Google Scholar 

  46. Goureau O, Bello(J, Thillaye B, Courtois Y, de Kozak Y. Increased nitric oxide production in endotoxininduced uveitis. J Immunol 1995;154:6518–6523.

    PubMed  CAS  Google Scholar 

  47. Jacquemin E, de Kozak Y, Thillaye B, Courtois Y, Goureau O. Expression of inducible nitric oxide synthase in the eye from endotoxin-induced uveitis rats. Invest Ophthalmol Vis Sci 1996; 37:1187–1196.

    PubMed  CAS  Google Scholar 

  48. Allen JB, McGahan MC, Ferrell JB, Adler KB, Fleisher LN. Nitric oxide synthase inhibitors exert differential time-dependent effects on LPS-induced uveitis. Exp Eye Res 1996;62:21–28.

    Article  PubMed  CAS  Google Scholar 

  49. Mandai M, Yoshimura N, Yoshida M, Iwaki M, Honda Y. The role of nitric oxide synthase in endotoxin-induced uveitis: effect of NG-nitro L-arginine. Invest Ophthalmol Vis Sci 1994;35:3673–3680.

    PubMed  CAS  Google Scholar 

  50. Dighiero P, Reux I, Hauw JJ, Fillet AM, Courtois Y, Goureau O. Expression of inducible nitric oxide synthase in cytomegalovirus-infected glial cells of retinas from AIDS patients. Neurosci Letter 1994;166:31–38.

    Article  CAS  Google Scholar 

  51. Ruderman NB, Williamson JR, Brownlee M. Glucose and diabetic vascular disease. FASEB J 1992;6:2905–2914.

    PubMed  CAS  Google Scholar 

  52. Williamson JR, Kilo C, Tilton RGMechanisms of glucose-and diabetes-induced vascular dysfunction in Hyperglycemia Diabetes and Vascular DiseaseN.B. Ruderman, J.R. Williamson, and M. Brownlee, Editor. 1992, Oxford University Press: New York. p. 107–132.

    Google Scholar 

  53. Winegrad Al. Does a common mechanism induce the diverse complications of diabetes? Diabetes 1987;36:396–406.

    Google Scholar 

  54. Williamson JR, Tilton RG, Kilo CThe Polyol Pathway and Diabetic Vascular ComplicationsinDiabetic Complications: Epidemiology and Pathogenetic MechanismsD. Andreaniet al.Editor. 1991, Raven Press: New York. p. 45–58.

    Google Scholar 

  55. Tilton R, Chang K, Pugliese G, Eades D, Province M, Sherman W, Kilo C, Williamson J. Prevention on hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes 1989;38:1258–1270.

    Article  PubMed  CAS  Google Scholar 

  56. Tilton RG, Chang K, Weigel C, Kilo C, Williamson JR. Increased ocular blood flow and ’25I-albumin permeation in galactose-fed rats: Inhibition by sorbinil. Investigative Ophthalmology & Visual Science 1988;29:861–868.

    CAS  Google Scholar 

  57. Williamson JR, Ostrow E, Eades DM, Chang K, Allison W, Kilo C, Sherman WR. Glucose-induced microvascular functional changes in nondiabetic rats are stereospecific and are prevented by an aldose reductase inhibitor. J Clin Invest 1990;85:1167–1172.

    Article  PubMed  CAS  Google Scholar 

  58. Williams B. Glucose-induced vascular smooth muscle dysfunction: the role of protein kinase C. J Hypertension 1995;13:477–486.

    Article  CAS  Google Scholar 

  59. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, Van den Enden M, Kilo C, Tilton RG. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993;42:801–813.

    Article  PubMed  CAS  Google Scholar 

  60. Kador PF, Akagi Y, Takahashi Y, Ikebe H, Wyman M, Kinoshita JH. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol 1990;108:1301–1309.

    Article  PubMed  CAS  Google Scholar 

  61. Engerman RL, Kern TS. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs. Diabetes 1993;42:820–825.

    Article  PubMed  CAS  Google Scholar 

  62. R.G. Tilton, K. Chang, J.R. Nyengaard, M. Van den Enden, Y. Ido, J.R. Williamson. Inhibition of sorbitol dehydrogenase. Effects on vascular and neural dysfunction in streptozocin-induced diabetic rats. Diabetes. 1995; 44:234–242.

    Article  PubMed  CAS  Google Scholar 

  63. M.J. Stevens, J. Dananberg, E.L. Feldman, S.A. Lattimer, M. Kamijo, T.P. Thomas, H. Shindo, A.A.F. Sima, D.A. Greene. The linked roles of nitric oxide, aldose reductase and (Na+,K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J. Clin. Invest.,1994; 94: 853–859.

    Article  PubMed  CAS  Google Scholar 

  64. M.F. Lou, J.R.J. Dickerson, R. Garadi, B.M. York. Glutathione depletion in the lens of galactosemic and diabetic rats. Exp. Eye Res., 1988;46: 17–530.

    Article  Google Scholar 

  65. I. Obrosova, J. Marvel, A.M. Faller, and J.R. Williamson. Reductive stress is a very early metabolic imbalance in sciatic nerve in diabetic and galactose-fed rats. Diabetologia, 1995;38: A8.

    Google Scholar 

  66. Tilton RG, Chang K, Hasan KS, Smith SR, J.M. P, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML, Williamson JR. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 1993;42:221–232.

    Article  PubMed  CAS  Google Scholar 

  67. Hasan KS, Chang W, Allison A, Faller A, Santiago JV, Tilton RG, Williamson JR. Glucose-induced increases in regional blood flow are prevented by aminoguanidine and L-NMMA, inhibitors of nitric oxide synthase. FASEB J 1993;7:105.

    Google Scholar 

  68. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue florescence in streptozocin-induced diabetic rat. Diabetes 1991;40:1328–1334.

    Article  PubMed  CAS  Google Scholar 

  69. Hammes H-P, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci. USA 1991;88:11555–11558.

    Article  CAS  Google Scholar 

  70. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986;232:1629–1632.

    Article  PubMed  CAS  Google Scholar 

  71. Picard S, Parthasarathy S, Fruebis J, Witztum JL. Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsuquent increase in uptake by macrophage scavenger receptors. Prox Natl Acad Sci USA 1992;89:6876–6880.

    Article  CAS  Google Scholar 

  72. Hasan KS, Chang K, Allison W, Santiago JV, Tilton RG. Aminoguanidine-induced increases in mean arterial blood pressure are suppressed in diabetic rats and normalized by sorbinil. Diabetes 1992;41:195A.

    Google Scholar 

  73. Kamata K, Miyata N, Kasuya Y. Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Brit. J. of Pharmacol. 1989;97:614–618.

    CAS  Google Scholar 

  74. Pelligrino DA, Albrecht RF. Chronic hyperglycemic diabetes in the rat is associated with a selective impairment of cerebral vasodilatory responses. J Cerebral Blood Flow and Metabolism 1991;11:667–677.

    Article  CAS  Google Scholar 

  75. Cameron NE, Cotter MA. Impaired contraction and relaxation in aorta from streptozotocin-diabetic rats: role of polyol pathway. Diabetologia 1992;35:1011–1019.

    Article  PubMed  CAS  Google Scholar 

  76. Heygate KM, Lawrence IG, Bennett MA, Thurston H. Impaired endothelium-dependent relaxation in isolated resistance arteries of spontaneously diabetic rats. Brit J Pharmacol 1995;116:3251–3259.

    Article  CAS  Google Scholar 

  77. Pieper GM, Moore-Hilton G, Roza AM. Evaluation of the mechanism of endothelial dysfunction in the genetically-diabetic BB rat. Life Sciences 1996;58:PL147–PL152.

    Article  PubMed  CAS  Google Scholar 

  78. Langenstroer P, Pieper GM. Regulation of spontaneous EDRF release in diabetic rat aorta by oxygen free radicals. Am J Physiol 1992;263((Heart Circ. Physiol. 32)):H257–H265.

    PubMed  CAS  Google Scholar 

  79. Hattori Y, Kawasaki H, Abe K, Kanno M. Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetic rat aorta. Am J Physiol 1991;261((Heart Circ. Physiol. 30)):H1086–H1094.

    Google Scholar 

  80. Mayhan WG. Impairment of endothelium-dependent dilatation of the basilar artery during diabetes mellitus. Brain Res 1992;580:297–302.

    Article  PubMed  CAS  Google Scholar 

  81. Tesfamariam B, Brown ML, Deykin D, Cohen RA. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J. Clin. Invest. 1990;85:929–932.

    Article  PubMed  CAS  Google Scholar 

  82. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am. J. of Physiol. 1992;263 (Heart Circ. Physiol. 32):H321–H326.

    CAS  Google Scholar 

  83. Lash JM, Bohlen HG. Structural and functional origins of suppressed acetylcholine vasodilation in diabetic rat intestinal arterioles. Circ Res 1991;69:1259–1268.

    Article  PubMed  CAS  Google Scholar 

  84. Mayhan WG, Simmons LK, Sharpe GM. Mechanism of impaired responses of cerebral arterioles during diabetes mellitus. Am J Physiol 1991;260:H319–H326.

    PubMed  CAS  Google Scholar 

  85. Simon BC, Cohen RA. EDTA influences reactivity of isolated aorta from hypercholesterolemic rabbits. Am J Physiol 1992;262:H1606–H1610.

    PubMed  CAS  Google Scholar 

  86. Fortes ZB, Lerne G, Scivoletto R. Vascular reactivity in diabetes mellitus: role of the endothelial cell. Br J Pharmacol 1983;79:771–781.

    Article  PubMed  CAS  Google Scholar 

  87. Head R, Longhurst P, Panek R, Stitzel R. A contrasting effect of the diabetic state upon the contractile responses of aortic preparations from the rat and rabbit. Br J Pharmacol 1987;91:275–286.

    Article  PubMed  CAS  Google Scholar 

  88. Tesfamariam B, Cohen RA. Role of superoxide anion and endothelium in vasoconstrictor action of prostaglandin endoperoxide. Am. J. of Physiol. 1992;262:H1915–H1919.

    CAS  Google Scholar 

  89. Bohlen HG, Lash JM. Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat arterioles. Am J Physiol 1993;265(Heart Circ. Physiol. 34):H219–H225.

    PubMed  CAS  Google Scholar 

  90. Tilton RG, Baier LD, Harlow JE, Smith SR, Ostrow E, Williamson JR. Diabetes-induced glomerular dysfunction: Links to a more reduced cytosolic ratio of NADH/NAD’. Kidney International 1992;41:778–788.

    Article  PubMed  CAS  Google Scholar 

  91. Cavallini L, Valente M, Rigobello MP. The protective action of pyruvate on recovery of ischemic rat heart: comparison with other oxidizable substrates. J Mol Cell Cardiol 1990;22:143–154.

    Article  PubMed  CAS  Google Scholar 

  92. Minchenko A, Bauer T, Salceda S, Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest 1994;71:374–379.

    PubMed  CAS  Google Scholar 

  93. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995;113:1538–1544.

    Article  PubMed  CAS  Google Scholar 

  94. Williamson JR, Chang KC, Stephan CC, Brock TA, Tilton RG. Links between retinal vascular dysfunction induced by elevated glucose levels and VEGF. Invest Ophthalmol Vis Sci 1996;37:S969.

    Google Scholar 

  95. Sone S, Kawakami Y, Okuda Y, Kondo S, Hanatani M, Suzuki H, Yamashita K. Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells. Biochem Biophys Res Comm 1996;221:193–198.

    Article  PubMed  CAS  Google Scholar 

  96. Ku DD, Zaleski JK, Liu S,.Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993;265:H586–H592.

    PubMed  CAS  Google Scholar 

  97. Morbidelli L, Chang C-H, Douglas JG, Granger HJ, Ledda F, Ziche M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol 1996;270:H411–H415.

    PubMed  CAS  Google Scholar 

  98. Yang R, Thomas GR, Bunting S, Ko A, Ferrara N, Keyt B, Ross J, Jin H. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 1996;27:838–844.

    Article  PubMed  CAS  Google Scholar 

  99. Arnet UA, McMillan A, Dinerman JL, Ballermann B, Lowenstein CJ. Regulation of endothelial nitric oxide synthase during hypoxia. J Biol Chem 1996;271:15069–15073.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cellular Biology, Texas Biotechnology Corporation, 7000, Fannin Houston, Texas, USA

    Ronald G. Tilton

Authors
  1. Ronald G. Tilton
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical College of Georgia, Augusta, Georgia

    Keith Green  & David S. Hull  & 

  2. Emory University, Atlanta, Georgia

    Henry F. Edelhauser

  3. Alcon Laboratories, Inc., Fort Worth, Texas

    Robert B. Hackett

  4. Morehouse School of Medicine, Atlanta, Georgia

    David E. Potter

  5. University of South Carolina School of Medicine, Columbia, South Carolina

    Ramesh C. Tripathi

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Tilton, R.G. (1997). Role of Nitric Oxide in Vascular Dysfunction Associated with Ocular Diseases. In: Green, K., Edelhauser, H.F., Hackett, R.B., Hull, D.S., Potter, D.E., Tripathi, R.C. (eds) Advances in Ocular Toxicology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5937-5_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5937-5_17

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7720-7

  • Online ISBN: 978-1-4615-5937-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation